MXPA06001286A - Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter. - Google Patents

Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter.

Info

Publication number
MXPA06001286A
MXPA06001286A MXPA06001286A MXPA06001286A MXPA06001286A MX PA06001286 A MXPA06001286 A MX PA06001286A MX PA06001286 A MXPA06001286 A MX PA06001286A MX PA06001286 A MXPA06001286 A MX PA06001286A MX PA06001286 A MXPA06001286 A MX PA06001286A
Authority
MX
Mexico
Prior art keywords
substituted
inflammation
alkyl
statin
ether
Prior art date
Application number
MXPA06001286A
Other languages
English (en)
Inventor
Daniel Lawrence Hartman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA06001286A publication Critical patent/MXPA06001286A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En este documento se describen metodos para el tratamiento y prevencion de la inflamacion y enfermedades asociadas con la inflamacion, mediante la coadministracion a un paciente que lo necesite de un dialquil eter, alquilo sustituido, aril-alquilo sustituido. dialquil tioeter sustituido, dialquil cetona sustituida, alquilo sustituido, o una sal farmaceuticamente aceptable de dicho dialquil eter, alquilo sustituido, aril-alquilo sustituido, dialquil tioeter sustituido, dialquil cetona sustituida, o alquilo sustituido, y una estatina o una sal farmaceuticamente de dicha estatina.
MXPA06001286A 2003-07-31 2004-07-19 Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter. MXPA06001286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49207603P 2003-07-31 2003-07-31
PCT/IB2004/002451 WO2005009431A1 (en) 2003-07-31 2004-07-19 Methods for treating inflammation and inflammation-associated diseases with a statin and ether

Publications (1)

Publication Number Publication Date
MXPA06001286A true MXPA06001286A (es) 2006-04-11

Family

ID=34103026

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001286A MXPA06001286A (es) 2003-07-31 2004-07-19 Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter.

Country Status (7)

Country Link
US (1) US20050026979A1 (es)
EP (1) EP1651205A1 (es)
JP (1) JP2007500690A (es)
BR (1) BRPI0413083A (es)
CA (1) CA2534178A1 (es)
MX (1) MXPA06001286A (es)
WO (1) WO2005009431A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
MX2007010233A (es) 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
US20090253654A1 (en) * 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
CA2716671A1 (en) * 2008-02-27 2009-09-03 Thommen Medical Ag Implant and method for the manufacture thereof
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
CN108434138A (zh) * 2013-03-15 2018-08-24 小利兰·斯坦福大学托管委员会 用于治疗与炎症相关的疾病的去乙基羟氯喹
US20180297929A1 (en) * 2017-04-18 2018-10-18 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU7100898A (en) * 1997-04-02 1998-10-22 Brigham And Women's Hospital Means of ascertaining an individual's risk profile for atherosclerotic disease
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
JP2006501238A (ja) * 2002-08-22 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 骨関節炎を治療する方法
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
EP1572189A1 (en) * 2002-11-15 2005-09-14 Warner-Lambert Company LLC Method of lowering crp and reducing systemic inflammation

Also Published As

Publication number Publication date
US20050026979A1 (en) 2005-02-03
CA2534178A1 (en) 2005-02-03
BRPI0413083A (pt) 2006-10-03
WO2005009431B1 (en) 2005-03-17
EP1651205A1 (en) 2006-05-03
WO2005009431A1 (en) 2005-02-03
JP2007500690A (ja) 2007-01-18

Similar Documents

Publication Publication Date Title
MXPA06001286A (es) Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter.
EG25822A (en) Quinolinyl-pyrrolopyrazoles
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MXPA05003302A (es) Compuestos de piperazina terapeuticos.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
HK1071310A1 (en) Combination therapy for the treatment of cancer
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
TNSN07474A1 (en) Dosage regimen for prasugrel
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
BR0315629A (pt) Método para baixar a cpr e reduzir a inflamação sistêmica
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
PT1220676E (pt) Prevencao do cancro colorrectal
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
WO2020264201A8 (en) Lemborexant for treating sleep issues
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
TW200505412A (en) Pharmaceutical compositions including an ether and selective cox-2 inhibitor and methods for using such
NO20043774L (no) The use of devazenide as analgesic agent
UA6522U (en) Method for treating patients with multiple and combined injuries of long bones
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
FA Abandonment or withdrawal